

NextSource Biotechnology Launches New Strategic Approach to Mitigate Slow-Downs in Manufacturing of Matured Medications in High Demand

NextSource Biotechnology Re-Introduces Critical Oncology Medication avoiding major losses in the Healthcare Sector

MIAMI, Sept. 23, 2013 /PRNewswire/ -- NextSource Biotechnology, LLC., (NSB), a leading Specialty Pharmaceutical Manufacturing and Marketing company with a strategic objective of Consolidating, Re-Branding and launching a "Matured & Orphan Drugs" product portfolio in the U.S. and International Healthcare Markets. By utilizing a worldwide distribution network as a key synergistic approach to aggressively build out our pipeline of products, we have aligned our plan with all regulatory requirements needed to gain expedited FDA approvals, Aligned Drug Portfolio selections and structured a plan to maximize production through our international globalization partnership.

The "Matured Drugs, Orphan Drugs and Discontinued Medications currently contribute to many of the existing deficiencies in all Healthcare Markets. These deficiencies have broadened the U.S. Healthcare Market's dependency on having to import over 80% of existing Prescription Medications from Manufacturers throughout the world. In addition, due the discontinuation of many high value Matured Drugs; the Healthcare market has reached a record high in FDA Short Supply. This problem has created a multi-billion dollar dependency on Non-FDA Approved Compounding Pharmacies.

At NSB, our goal is to ensure the Healthcare Markets continued access to these important medications. All products in the NSB portfolio share development factors that Cross Over the Human Healthcare market yielding additional indications for use in Companion Animals. These initiatives will optimize, secure and diversify the product portfolio yielding the highest revenue potential while maintaining the most secure supply chain.

"Due to current market conditions, "said Robert DiCrisci, President, CEO of NextSource Biotechnology, we are strategically positioned to launch a product portfolio that will further anchor our position as the leader in product re-branding and product diversification of the "Matured & Orphan Drugs". Our future remains focused on maximizing our existing portfolio of products, while maintaining flexibility to bring in additional products as demands change."

NSB's core competencies in marketing and business development enabled us to engage in high volume distribution agreements with the top Wholesalers in the US Market which currently account for high volume nationwide distribution on over 70% of our revenue.

NextSource Biotechnology recently re-introduced the Lomustine (CCNU) product formally known as CeeNu® through an exclusive manufacturing partnership with CordenPharma, Latina. This business development was the result of a divestiture between Bristol-Myers Squibb (BMS) and CordenPharma\NextSource Biotechnology. NSB is currently in the final stage of normalizing the shortage of Lomustine (formally known as CeeNu®) in the U.S. healthcare market. NSB is projected to be off short supply by the close of Q3, 2013. The medication will continue to be distributed under the Lomustine label pending FDA "Brand" name review and approval.

Lomustine has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in the following:

Brain tumors—both primary and metastatic, in patients who have already received appropriate surgical and/or radio therapeutic procedures.

Hodgkin's disease—secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

About our Partner: CordenPharma is an expert Contract Manufacturing partner helping leading pharmaceutical and biotechnology companies link their requirements for product success with their patients' healthier lives.

Formed as a pharmaceutical branch of [International Chemical Investors Group](#) in 2006, CordenPharma provides specialized technologies that are ideal for the development and manufacturing of oral, sterile, highly potent and antibiotic pharmaceutical Drug Products, their Active Pharmaceutical Ingredients, and associated Global Supply Chain and Packaging Services.